nct_id: NCT05927571
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-07-03'
study_start_date: '2023-08-10'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Tocilizumab'
  - drug_name: 'Drug: Cevostamab'
  - drug_name: 'Drug: Elranatamab'
long_title: An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics,
  and Activity of the Combination of Cevostamab and Elranatamab in Patients With Relapsed
  or Refractory Multiple Myeloma
last_updated: '2025-11-18'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Genentech, Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 120
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1'
- '* Diagnosis of R/R MM per IMWG criteria'
- '* For female participants of childbearing potential: agreement to remain abstinent
  or use contraception'
- '* For male participants: agreement to remain abstinent or use a condom'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Prior treatment with cevostamab or another agent targeting fragment
  crystallizable receptor-like 5 (FcRH5)
- Exclude - * Prior treatment with elranatamab
- Exclude - * Prior allogeneic stem cell transplantation (SCT)
- Exclude - * Absolute plasma cell count exceeding 500 per milliliter (mL) or 5% of
  the peripheral blood white cells
- "Exclude - * Diagnosis of Waldenstr\xF6m macroglobulinemia or polyneuropathy, organomegaly,\
  \ endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome"
- Exclude - * Participants with known history of amyloidosis
- Exclude - * History of autoimmune disease
- Exclude - * History of confirmed progressive multifocal leukoencephalopathy
- Exclude - * Peripheral motor polyneuropathy of prespecified grade
- Exclude - * Known or suspected chronic cytomegalovirus (CMV) and/or Epstein-Barr
  virus (EBV) infection
- Exclude - * Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage
  activation syndrome (MAS)
- Exclude - * Acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV)
  infection
- Exclude - * Human immunodeficiency virus (HIV) seropositivity
- Exclude - * History of central nervous system (CNS) myeloma disease
- Exclude - * Significant cardiovascular disease
short_title: A Study Evaluating the Safety, Pharmacokinetics, and Activity of the
  Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory
  Multiple Myeloma (R/R MM)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Genentech, Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of the study is to evaluate safety and tolerability of the combination
  of cevostamab plus elranatamab and also determine the recommended Phase II regimen
  (RP2R) for the study treatment. The study consists of a safety lead-in stage, and
  an expansion stage.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Safety Lead-In Cohort
      arm_internal_id: 0
      arm_description: Participants will receive cevostamab, intravenously (IV), in
        combination with elranatamab, subcutaneously (SC), with step-up dosing of
        each drug in pre-phase following which they will receive elranatamab, at the
        assigned dose as a SC injection until disease progression or unacceptable
        toxicity. Participants will also receive cevostamab at the assigned dose as
        IV infusion until disease progression or unacceptable toxicity or up to 1
        year on treatment, whichever occurs first.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Cevostamab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Elranatamab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Tocilizumab'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Dose Expansion Cohort (Combined Therapy)
      arm_internal_id: 1
      arm_description: Participants will receive cevostamab, IV, in combination with
        elranatamab, SC, with step-up dosing in pre-phase following which they will
        receive elranatamab, at the assigned dose as a SC injection until disease
        progression or unacceptable toxicity. Participants will also receive cevostamab
        at the assigned dose as IV infusion until disease progression or unacceptable
        toxicity or up to 1 year on treatment, whichever occurs first.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Cevostamab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Elranatamab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Tocilizumab'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Dose Expansion Cohort (Monotherapy)
      arm_internal_id: 2
      arm_description: Participants will receive elranatamab SC, with step-up dosing
        in pre-phase following which they will receive elranatamab, at the assigned
        dose as a SC injection until disease progression or unacceptable toxicity.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Elranatamab'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Refractory
        oncotree_primary_diagnosis: Lymphoid Neoplasm
